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SE – Standard Error 
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TNF-α – Tumor Necrosis Factor Alpha 
T-PER – Total Protein Extraction Reagent 
TXRF – Total-Reflection X-Ray Fluorescence Spectrometer 
VTA – Ventral Tegmental Area 
WST – Water-Soluble Tetrazolium Salt 
Y – Yttrium 
Zn – Zinc 
18S – 18S Ribosomal Subunit 
1 
 
  TABLE OF CONTENTS 
BACKGROUND ................................................................................................................4 
METHODS .......................................................................................................................12 
Animal Care ..................................................................................................................13 
Treatment Injections......................................................................................................13 
Animal Sacrifice............................................................................................................13 
Brain Harvest ................................................................................................................14 
Brain Microdissection ...................................................................................................14 
Brain Tissue X-Ray Fluorescence Spectroscopy ..........................................................15 
Plasma X-Ray Fluorescence Spectroscopy ...................................................................15 
Protein Purification .......................................................................................................16 
Protein Quantification ...................................................................................................16 
Superoxide Dismutase Activity Assay ..........................................................................16 
Evans Blue Protocol ......................................................................................................17 
Evans Blue Histology ....................................................................................................17 
Evans Blue Microscopy and Analysis...........................................................................18 
RNA Isolation ...............................................................................................................18 
RNA Quantification ......................................................................................................19 
Real-time Polymerase Chain Reaction .........................................................................19 
PCR Analysis ................................................................................................................20 
Statistical Testing ..........................................................................................................21 
RESULTS .........................................................................................................................34 
Significant Difference in Metal Concentrations in Midbrain .......................................35 
Elemental Analysis of Mouse Plasma ...........................................................................35 
Superoxide Dismutase Activity in Brain Homogenate .................................................36 
Evidence of Blood-Brain Barrier Permeability via Evans Blue Assay .........................37 
Significant Changes in DNA Transcription via qPCR Analysis ...................................37 
DISCUSSION ...................................................................................................................56 
2 
 
CONCLUSION ................................................................................................................64 
REFERENCES .................................................................................................................67 
EQUATIONS 
Equation 1. Determination of SOD activity by determination of percent inhibition of enzyme
 .......................................................................................................................................22 
TABLES 
Table 1. Superoxide Dismutase Reaction Well Setup ..................................................23 
Table 2. Master Mix Preparation for qPCR ..................................................................24 
Table 3. Optimized Primer Annealing Temperatures for qPCR ...................................35 
Table 4. Total Reflection X-Ray Fluorescence Spectroscopy values of murine prefrontal 
cortex .............................................................................................................................38 
Table 5. Total Reflection X-Ray Fluorescence Spectroscopy values of murine striatum 
 .......................................................................................................................................39 
Table 6. Total Reflection X-Ray Fluorescence Spectroscopy values of murine midbrain
 .......................................................................................................................................40 
Table 7. Elemental concentrations in mouse plasma analyzed by TXRF .....................41 
Table 8. Counts per pixel measurements of Evans Blue permeability in Saline and METH-
treated mice ...................................................................................................................42 
Table 9. Fold Change Values for IL-1β and MT3 mRNA Expression Determined via PCR
 .......................................................................................................................................43 
FIGURES 
Figure 1. Brief initial synopsis of the METH-induced neurodegenerative process ......11  
Figure 2. Macro- and microdissection regions of murine brain ....................................26 
Figure 3. TXRF Spectrum of murine plasma sample ...................................................27 
Figure 4. TXRF Spectrum of murine midbrain sample ................................................28 
Figure 5. Representative brain slices for Evans Blue Staining analysis of PFC ...........29 
Figure 6. Representative brain slices for Evans Blue Staining analysis of STR...........30 
Figure 7. Representative brain slices for Evans Blue Staining analysis of MB ............31 
Figure 8. IL-1β primer optimization and melting curve ...............................................32 
Figure 9. MT3 primer optimization and melting curve ................................................33 
3 
 
Figure 10. Elemental changes measured by TXRF in PFC of saline and METH treated mice
 .......................................................................................................................................44 
Figure 11. Elemental changes measured by TXRF in STR of saline and METH treated mice
 .......................................................................................................................................45 
Figure 12. Significant element increases in the midbrains of METH treated mice ......46 
Figure 13. Elemental concentrations in mouse plasma .................................................47 
Figure 14. Iron concentrations in mouse plasma ..........................................................48 
Figure 15. Percent inhibition of Copper-Zinc Superoxide Dismutase in mouse MB samples
 .......................................................................................................................................49 
Figure 16. Protocol optimization of Copper-Zinc Superoxide Dismutase Assay .........50 
Figure 17. Whole brains after Evans Blue treatment ....................................................51 
Figure 18. Determination of Blood-Brain Barrier Permeability by Evans Blue Assay 52 
Figure 19. qPCR Data of IL-1β and MT3 from murine PFC ........................................53 
Figure 20. qPCR Data of IL-1β and MT3 from murine STR .......................................54 
Figure 21. qPCR Data of IL-1β and MT3 from murine MB .........................................55 
Figure 22. Summation of known and experimentally derived data ..............................63 
 
  
4 
 
 
 
 
 
 
 
 
BACKGROUND 
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Methamphetamine (METH) is a widely used drug of abuse in the United States (NIDH 2013). The 
characteristic “high” associated with METH intoxication comes from the excessive release of 
dopamine (DA) into the neuronal synapse. The oxidative damage due to DA release is amplified 
by blocked reuptake of the neurotransmitter (Ajjimaporn et al., 2005; Ajjimaporn et al., 2008; 
Cadet et al., 1994; Mirecki, 2004). During the increased time in the synapse, DA causes irreparable 
damage to the neuron terminals leaving lasting effects on the brain (Cadet et al., 1994; Riddle et 
al., 2006). In the laboratory, the damaging effects of METH are used to model neurodegenerative 
disease states that affect the dopaminergic pathways. Three major dopaminergic pathways exist in 
the brain. The mesocortical pathway begins in the ventral tegmental area (VTA) and extends to 
the prefrontal cortex (PFC). The mesolimbic pathway projects from the VTA to the striatum 
(STR). The nigrostriatal pathway projects from the substantia nigra (SN) to the STR. Due to their 
close proximity, for the purpose of this thesis, the SN and VTA are paired together and collectively 
referred to as the midbrain (MB). Dopaminergic cell bodies reside in the MB and project their 
axons to the PFC and STR. Therefore, all three regions (PFC, STR, and MB) are key in studying 
the neurotoxic effects of METH. 
 
A mouse model (adult C57BL/6J males) was chosen for their wild type characteristics and normal 
neurological function, making a suitable model for studying the effects of drug treatment and 
addiction. The doses of METH used in the literature range from subacute doses at 0.5 mg/kg 
(Shanks et al., 2015) to large doses reaching 30 mg/kg (Ares-Santos et al., 2014; Carmena et al., 
2016). Higher doses may be used to model acute administration of METH and bring about 
extensive neurodegeneration (Bowyer et al., 2008). Our dose of 5 mg/kg METH is moderate, 
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insuring a physiological effect without causing widespread death of dopaminergic neurons. For 
our studies, a chronic 10-day drug treatment was to model METH abuse in humans. 
 
Though it is the most widely cited effect of METH, DA release is not the only detrimental result 
of METH use. Blood-brain barrier leakage, hyperthermia, potassium influx, edema, mitochondrial 
dysfunction, and inflammation may all result from METH intoxication (Aizenman et al., 2010; 
Ajjimaporn et al., 2005; Riddle et al., 2006). These consequences of METH treatment often work 
in parallel, making it difficult to separate cause and effect. 
 
The blood-brain barrier (BBB) functions to protect the brain from harmful substances in peripheral 
circulation. Tight junctions between astrocytes and pericytes surrounding blood vessels in the brain 
work to prevent large or charged molecules from passing through (Luissiant et al., 2012). Due to 
its lipophilicity, METH is able to easily pass through the BBB. High doses of METH can cause a 
breakdown of the BBB and may allow ions or proteins to pass through into the brain (Bowyer et 
al., 2008; Northrop & Yamamoto, 2015; Turowski & Kenny, 2015). This unregulated passage of 
potentially damaging materials may cause brain edema and can lead to CNS damage and cell death 
(Turowski & Kenny, 2015). A potential mechanism for the BBB disruption is METH-induced 
hyperthermia. Hyperthermia is a state of elevated body temperatures, and in this case, is most 
noticeable in the brain (Brown et al., 2002). Studies have shown that hyperthermia is necessary for 
BBB leakage, though the exact relationship between METH and BBB leakage is not currently 
known (Northrop & Yamamoto, 2015; Turowski & Kenny, 2015). Commonly, questions of BBB 
permeability are answered by Evans Blue (EB) assay (Manaenko et al., 2011). EB dye is a large 
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molecule that binds to plasma albumin, which may only cross into the brain if the BBB is disrupted 
in some way. If EB dye is allowed to pass into the brain, the compromised brain region will 
accumulate the dye and, in extreme cases, may even appear blue. 
 
Brain edema following METH treatment is well documented and intertwined with both 
hyperthermia and BBB disruption (Sharma & Hoopes, 2003). A study by Kiyatkin et al. 2007 
presented hyperthermia, BBB disruption, and increased ion concentrations as major effects of 
METH treatment. Increases in Chlorine (Cl), Sodium (Na), and Potassium (K) are associated with 
increased water influx, called edema, and were all noted after treatment of rats with a 9 mg/kg 
dose of METH (Kiyatkin et al., 2007). Ion influx is likely a precursor to brain edema, as net flow 
of water tends to be towards hyperosmotic tissues. The ion imbalances and influx of water 
characteristic of edema may be a fatal symptom of METH treatment. Brain edema may be 
responsible for cases of increased mortality after dosing of METH well below the lethal dose for 
50% of participants (LD50) (9 mg/kg; Kiyatkin et al., 2007). 
 
An increase in K+ in the brain may be due to mobilized microglia as part of the inflammatory 
response (Knoch et al., 2008). Subsequently, a study by Aizenman et al. 2010 found that the 
damage associated with METH intoxication was increased when microglia were present, leading 
to the belief that inflammation plays a key role in the damaging effects of METH. Microglia are 
part of the immune response in the brain. In the event of CNS damage, microglia are responsible 
for releasing proinflammatory cytokines, like interleukin 1 beta (IL-1β) and tumor necrosis factor 
alpha (TNF-α), nitric oxide (NO), superoxide species, and other signaling molecules (Loane & 
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Byrnes, 2010; Shanks et al., 2012). The formation of radical oxygen species (ROS) and nitrogen 
species (RNS) by microglia are fully dependent on the increase in K+ current and Zn2+ release 
(Knock et al., 2008). Likewise, production of ROS and RNS from local microglia may be brought 
about by METH (Ajjimaporn et al., 2005). Therefore, it is reasonable to assert that METH 
treatment causes CNS damage adequate to mobilize microglia and begin an inflammatory response 
(Fernandes et al., 2016). This inflammatory response is crucial in the dysregulation of homeostatic 
ion and metal concentrations in the brain. 
 
Iron serves a number of varied functions in the body from mitochondrial functioning to oxygen 
transport (Ward et al., 2014).  Initially, our studies focused on accumulation of iron in the spleen. 
In previous studies by Shanks et al (unpublished), dark spots were noticed on the spleens of 
METH-treated mice. These dark spots were thought to be excess heme, as the spleen functions to 
filter and recycle damaged red blood cells. Excess iron in peripheral organs like the spleen and 
liver may cause organ failure, which is a serious health risk (Badria et al., 2015). Imbalances in 
metal concentration in the brain are often found as a characteristic of neurological dysfunction, 
like Alzheimer’s disease (Alimonti et al., 2007; Andrasi et al., 2000). Neuroinflammation due to 
disorders like Alzheimer’s and Parkinson’s disease, mediated by cytokines like IL-1β and TNF-α, 
may cause an accumulation of iron in the brain (Li et al., 2016; Ji et al., 2016). Iron cannot be 
excreted in humans, and concentrations are monitored by changing the rate of absorption from 
food (Badria et al., 2015). With potential excess iron accumulation in peripheral organs, like the 
spleen, my thesis focuses on studying potential mechanism and effects of metal accumulation, 
including iron, zinc, and rubidium following neuroinflammation caused by METH treatment. 
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Zinc is an essential element for both plants and animals. Nearly three-quarters of zinc is transported 
throughout the body bound to plasma albumin (Roohani et al., 2013). Zinc plays a key role in the 
inflammatory pathway. Supplementation with zinc may decrease damaging effects of METH, 
while chelating the ion may increase damage caused by METH within the brain (Aizenman et al., 
2010; Bao et al., 2010). As noted previously, the inflammatory response includes production of 
ROS and RNS by microglia. Under normal circumstances, ROS are metabolized by several 
mechanisms within the body. Within normal ranges, zinc may act as an antioxidizing agent through 
superoxide dismutase (SOD) and metallothionein (MT) proteins (Tyszka-Gochara et al., 2014).  
 
Copper-zinc superoxide dismutase (CuZnSOD) is a member of the SOD family of enzymes and 
uses Cu and Zn as cofactors. Some amount of oxygen free radicals are formed as a byproduct of 
normal cell metabolic processes. CuZnSOD plays a role in neutralizing the free radicals formed 
before they have a chance to exert toxic effects on proteins or nucleic acids within the cell. 
CuZnSOD has shown an increase after METH treatment in some, but not all cases (Mirecki et al., 
2004). Metallothionein proteins are one of many zinc-transporting proteins found within cell 
membranes. MTs act to transport metals in or out of cells, also acting as a reservoir to maintain 
metal homeostasis by binding or releasing bound metal ions as necessary. Metallothionein-3 
(MT3) is specific to brain tissues, and may have free-radical neutralizing properties due to the 
presence of bound divalent metals, including Zn2+. These two proteins, as well as the homeostasis 
of intracellular zinc levels, are extremely important to the health of cells. Decreases in zinc levels 
may be linked to depression (Doboszewska et al., 2016) while excess zinc levels cause 
mitochondrial dysfunction (Ajjimaporn et al., 2005; Sensi et al., 2009; Weiss et al., 2014). Cell 
death may occur as excess zinc may activate proapoptotic cascades (Sensi et al., 2009; Pochwat et 
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al., 2015).  Excess zinc exerts mitochondrial toxicity by entering the organelle and disrupting the 
membrane potential (Tyszka-Gochara et al., 2014). ROS and RNS created following excessive 
zinc levels are likely due to the mitochondrial dysfunction (Weiss et al., 2014; Emoto et al., 2015), 
but may relate to other pathways, including nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, as well (Sensi et al., 2009).  
 
In the preliminary studies for this thesis, we determined that excess zinc was sequestered in the 
midbrains of METH-treated mice when compared to Saline-treated controls. Using that 
information, our studies of the relationship between METH intoxication and Zn2+ broaden the 
understanding of the damaging effects of this drug and metal accumulation in the brain. A wild-
type mouse model (male C57BL6J mice) was used to study the in vivo neurodegenerative process. 
Brain regions (PFC, STR, and MB) were chosen based on previously optimized lab protocols, due 
to the high prevalence of dopaminergic neurons in the reward pathway in those regions. A brief 
synopsis of this process may be found in figure 1. 
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Figure 1. Brief initial synopsis of the METH-induced neurodegenerative process. During the 
initial phase of this thesis research, an increase in zinc concentration in the midbrain was noted in 
METH-treated mice as compared to Saline-treated controls. Further studies consisted of the 
exploration of this phenomenon and search for potential mechanisms. 
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Animal Care 
Adult (n=66; average age=112.4 days ± 3.22) male C57BL/6J mice (Jackson Laboratory, Bar 
Harbor, ME) were housed in plastic cages on a 12-hour light/dark cycle. They were allowed food 
and water ad libitum. All procedures were performed in accordance to the Guide for the Care and 
Use of Laboratory Animals and established university laboratory procedures (Shanks et al. 2015). 
 
Treatment Injections 
C57BL/6J mice were weighed daily to determine dosing of drug treatment. Mice were given one 
intraperitoneal (IP) injection daily of either 5 mg/kg METH or 0.1 mL/10 g body mass of 0.9 % 
sterile saline (Saline). Treatment injections were administered each morning (0800) for 10 days.  
 
Animal Sacrifice 
On Day 10, 4 hours after the final treatment injection, animals were given an IP injection of 
Avertin. Avertin was prepared in accordance to established protocols by the Division of 
Laboratory Animal Resources at the University of Kentucky Medical Center. A timepoint of 4 
hours was chosen because it allowed most of the treatment drug to be metabolized, as may be 
noted by a return to normal ambulation levels in METH-treated mice. Once sufficiently 
anesthetized, the animals were decapitated and the brains were harvested.  
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Brain Harvest 
The brain was removed from the skull by first cutting the fur from the base of the skull to the nose. 
The skin was peeled back to reveal the skull beneath. The skull was cut in small sections and 
peeled away from the brain, starting from the hindbrain region and moving forward to the olfactory 
bulbs. Once the majority of the skull was removed, the ear bones were removed, the frontal bone 
between eye sockets was cut, and the brain was removed. Whole brains were either frozen at  
-80°C, or further microdissected and then frozen until use.  
 
Brain Microdissection  
After removal, the brain was placed in a chilled metal brain matrix. 2 mm slices containing the 
prefrontal cortex (PFC), striatum (STR), and midbrain (MB) were taken. Macro-incisions were 
made as shown in Figure 2A: Olfactory bulbs (0-2mm), prefrontal cortex (2-3 mm), striatum (4-5 
mm), and midbrain (9-10 mm). The center of the PFC was determined as 1.94 bregma, STR at 
0.50 bregma, and MB at -3.28 bregma, as shown in Figure 2B-D. PFC, STR, and MB 2 mm slices 
were further dissected under a dissection scope, and the regions of interest were either processed 
immediately or stored in labeled Eppendorf tubes at -80°C. Brain regions (PFC, STR, and MB) 
were chosen based on previously optimized lab protocols and the presence of many dopaminergic 
neurons in the reward pathway. 
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Brain Tissue X-Ray Fluorescence Spectroscopy 
Mice were injected with 5 mg/kg METH or 0.9% Saline for 10 days before sacrifice and brain 
dissection, as described previously. PFC, STR, and MB were homogenized by sonication. 100 μL 
of homogenized tissue was transferred to a separate Eppendorf tube and 10 μL of internal standard 
(Yttrium) was added. The sample was vortexed to mix components thoroughly. 10 μL of the new 
sample was transferred to a disposable acrylic disc and allowed to dry on a hot plate. The sample 
disc was analyzed by Bruker S2 PICOFOX Total-Reflection X-Ray Fluorescence spectrometer 
(TXRF). Each brain sample was run in triplicate for 1000 seconds (s) and turned clockwise 1/3 
each time, to account for any uneven pipetting of sample homogenate on the carrier disc (Figure 
3). 
 
Plasma X-Ray Fluorescence Spectroscopy 
After decapitation, blood was collected and centrifuged (12,000 RPM for 5 min) to pellet the red 
blood cells. Plasma was isolated and transferred to a labeled Eppendorf tube. 10 μL of internal 
standard (Yttrium) was added to 100 μL of plasma and the tube was vortexed. 10 μL of the 
prepared plasma sample was transferred to a disposable acrylic disc and allowed to dry on a hot 
plate. The sample discs were transferred to the TXRF for analysis. Plasma samples were run once 
each for 500 s (Figure 4). 
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Protein Purification 
Mice were injected with 5 mg/kg METH or 0.9% Saline for 10 days before sacrifice and brain 
dissection, as described previously. Microdissected brain tissue samples were sonicated in 1 mL 
Tissue Protein Extraction reagent (T-PER) per 0.05 g of tissue, as per supplier (Thermo 
Scientific®) recommendations. Homogenized samples were centrifuged at 10,000 rpm for 5 
minutes to pellet debris. Supernatant was pipetted into a labeled Eppendorf tube and stored at -
80°C. 
 
Protein Quantification 
Protein concentrations were determined by Bio-Rad Protein assay. The assay was conducted as 
per manufacturer (Bio-Rad®) instructions, although further dilutions were required to achieve 
measurable concentrations. Two-fold serial dilutions of bovine serum albumin (BSA) were created 
to make the standard curve. 10 μL of each BSA standard and protein sample was pipetted in 
triplicate into a 96-well plate. 200 μL of dye reagent was added to each well, and the plate was 
briefly centrifuged to remove any bubbles. The plate was allowed to incubate at room temperature 
for approximately 5 minutes before the absorbance was measured in a 96-well plate reader at 595 
nm. 
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Superoxide Dismutase Activity Assay 
Reagents were prepared as per manufacturer (Abcam) instructions. Briefly, 1 mL Water-soluble 
Tetrazolium Salt (WST) solution was diluted with 19 mL of SOD Assay Buffer. SOD Enzyme 
solution was centrifuged briefly and mixed by pipet. 15 μL of enzyme solution was diluted with 
2.5 mL of Dilution buffer. Materials and reagents were equilibrated to room temperature before 
assay was run. Reaction wells were prepared as shown in Table 1, with Enzyme Working Solution 
added last. 
Immediately after the enzyme working solution was added, the plate was incubated for 20 minutes 
at 37°C, then measured on a microplate reader at OD450 nm. Absorbance values for each sample 
(run in triplicate) were averaged. SOD activity for each sample was calculated based on equation 
1. 
Evans Blue Protocol 
Protocol was developed based on studies by Manaenko et al. 2010. Mice were injected with 5 
mg/kg METH or 0.9% Saline for 10 days, as described previously. On Day 10, 2.5 hours after the 
final treatment injection, an injection of 2% Evans Blue dye equal to the volume of treatment 
administered (0.1 mL/10 g body mass) was given IP. Evans Blue dye was allowed to circulate for 
1.5 hours before the animals were anesthetized by IP Avertin injection and brains were removed. 
Whole brains were immediately transferred to -80°C freezer. 
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Evans Blue Histology 
Frozen brains were removed from -80°C storage and placed into a chilled metal brain matrix. 
Brains were allowed to thaw for 2 minutes before being sliced into 1 mm sections, then returned 
to the freezer. Brain slices were removed from the brain matrix and transferred to microscope 
slides, returning to the freezer for 2 minutes whenever the tissue became too thawed to easily 
handle. When not in use, brain slices were stored at -80°C. PFC, STR, and MB slices were 
examined under a dissecting scope at 12x magnification. 
 
Evans Blue Microscopy and Analysis 
Microscope pictures were taken using OMAX® 0.5x Reduction Lens (A3RDF50). Pictures of 
magnified PFC, STR, and MB sections were taken at 12x magnification. Pictures of whole brains 
were taken at 7.5x magnification. Brain sections were grouped based on location in the atlas 
(Figures 5, 6, 7). Photographs of brain regions were converted from JPEG to 8-bit format to better 
differentiate individual colors. Pictures were analyzed by histogram for blue pixel concentration 
using ImageJ. Blue pixel values were recorded by a blind observer and later analyzed for 
significance. 
 
RNA Isolation 
Mice were injected with 5 mg/kg METH or 0.9% Saline for 10 days before sacrifice and brain 
dissection, as described previously. Microdissected PFC, STR, and MB samples were sonicated in 
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600 mL of lysis solution and transferred to RNase-free Eppendorf tubes. Tubes were centrifuged 
for 2 minutes at 12,000 RPM and the supernatant (approximately 550 μL) was transferred to 
another tube. An equal volume of 70% ethanol was added to the supernatant and the tubes were 
vortexed to mix. If loose debris was present in the tubes, they were centrifuged again at 12,000 
RPM for 1 minute. The RNA collection column was assembled with the collection tube. 
Approximately 600 μL of lysate and ethanol solution was applied to the column and it was 
centrifuged at 12,000 RPM for 1 minute. The flow-through was discarded, and the step is repeated 
with the remaining lysate and ethanol solution, again, discarding the remaining flow-through. 400 
μL of column wash solution was applied to the column and centrifuged for 1 minute, repeated once 
under identical conditions, then repeated again with 400 μL of wash solution but centrifuged for 
two minutes. Flow-through was discarded after each RNA wash. An elution tube was assembled 
to the column and 50 μL of elution buffer was added to the column. The column was centrifuged 
for 2 minutes at 1500 RPM, then for 1 minute at 12,000 RPM. The final flow-through containing 
purified RNA was placed on the column again and centrifuged once more to maximize the amount 
of RNA isolated. 
 
RNA Quantification 
Purified RNA concentrations for each sample were assessed by NanoDrop 1000 
spectrophotometry (Thermo Scientific®). RNA was diluted to 1 ng/mL concentrations before use. 
Both stock RNA and diluted RNA aliquots were stored at -20°C when not in use. 
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Real-time Polymerase Chain Reaction 
Primers were diluted to 1 μM solutions using 1 μL of stock primer solution (concentration 100 
μM) and 99 μL molecular grade H2O. Primer sequences are as follows:  
MT3 – 5’ CTGCTGGACTGGATATGGAC 3’ and 5’ CTCACTGGCAGCAGCTGCAT 3’ (Chen 
et al., 2004).  
IL-1β –  5’ CAACCAACAAGTGATATTCTCCAT 3’ and 5’ GATCCACACTCTCCAGCTGCA 
3’ (Linares et al., 2006).  
18S – 5’ CTGAGAAACGGCTACCACATC 3’ and 5’ CGCTCCCAAGATCCAACTAC 3’ 
(Abbas et al., 2011).   
Purified RNA was isolated, as described above, and used for replication. Verso SYBR Green qPCR 
master mix was prepared according to manufacturers’ (Thermo Scientific) suggestion and 
previously established lab protocol (Table 2). Plate layout was designed using Real-time 
Polymerase Chain Reaction (qPCR) software with each sample run in triplicate.  
qPCR Program was set to run as follows: 50°C for 15 minutes, 95°C for 15 minutes, 95°C for 15 
seconds, 55°C* for 30 seconds, 72°C for 30 seconds (*temperature varied by primer). Melting 
curves were added at the end of each thermal cycling program, to ensure the primers were 
functioning properly. Initial primer optimization included test plates of escalating RNA 
concentrations run at different temperatures until the optimum annealing temperature for each 
primer was found. Optimization was based on melting curves and primer efficiency calculations 
(Table 3; Figure 8-9). 
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PCR Analysis 
qPCR plates were analyzed for critical threshold (CT) value. CT value is determined as the point 
where each sample crosses the fluorescence threshold. First, CT values from each treatment gene 
were compared to CT values from the housekeeping gene (18S). This is to ensure standard amounts 
of RNA were being compared within treatment groups and gives the ΔCT value. To determine if 
significant changes in gene expression existed, statistics were run comparing ΔCT values for 
METH and Saline treatment groups. METH and Saline treatment groups were compared to 
determine the fold change in gene expression, giving the ΔΔCT value. 
 
Statistical Testing 
Group sizes and animal numbers were determined based on a number of factors, including previous 
experimental designs, information regarding variability, and power analysis. Paired t-tests for 
single comparisons and unpaired t-tests for comparison of single groups were performed when 
applicable. All data are expressed as means±SE. Statistical significance was accepted at p<0.05. 
Error bars represent standard error (SE). 
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𝑆𝑆𝑆𝑆𝑆𝑆 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (𝐴𝐴𝑖𝑖ℎ𝐴𝐴𝑖𝑖𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖 𝑟𝑟𝑟𝑟𝐴𝐴𝑟𝑟 %) =  (𝐴𝐴𝑖𝑖𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴1 –  𝐴𝐴𝑖𝑖𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴3) –  (𝐴𝐴𝐴𝐴𝑟𝑟𝐴𝐴𝐴𝐴𝐴𝐴𝑟𝑟 –  𝐴𝐴𝑖𝑖𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴2)(𝐴𝐴𝑖𝑖𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴1 − 𝐴𝐴𝑖𝑖𝐴𝐴𝑟𝑟𝑖𝑖𝐴𝐴3)  ∗  100 
 
 
Equation 1. Determination of SOD activity by determination of percent inhibition of enzyme. 
Absorbance values from blank wells were compared to absorbance values from each sample 
well. These values were then converted to a percent and reported as percent inhibition of 
enzyme. 
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Table 1. Superoxide Dismutase Reaction Well Setup. Setup was proposed by Abcam in 
accordance with their Superoxide Dismutase Activity Colorimetric Assay kit (ab65354). Assay 
was performed in a standard colorimetric 96-well plate. 
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Table 2. Master Mix Preparation for qPCR. Master mix was prepared for each primer in 
accordance with kit protocols and standard lab procedure.  
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Table 3. Optimized Primer Annealing Temperatures for qPCR. Annealing temperature 
optimization is crucial to ensure primers anneal to the proper target and not a different, non-
specific sequence. **18S served as our housekeeping gene and had been previously optimized by 
the lab of Dr. Shanks and Dr. Lloyd. 
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A.        B. 
 
C.       D. 
 
 
 
 
 
 
 
Figure 2. Macro- and microdissection regions of murine brain. A. Macrodissection landmarks for 
whole murine brain as may be shown in metal brain matrix: PFC 2-3 mm, STR 4-5 mm, and MB 
9-10 mm. B. Microdissection region of murine PFC; approx. 1.94 bregma. C. Microdissection 
region of murine STR; approx. 0.50 bregma. D. Microdissection region of murine MB; approx.     
-3.28 bregma. 
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Figure 3. TXRF Spectrum of murine plasma sample. Blood was extracted from decapitated mice 
and centrifuged for 5 minutes at 12,000 RPM to separate out plasma. 10 μL of Yttrium (Y) was 
added to 100 μL of plasma, and 10 μL of the mixture was pipetted onto an acrylic carrier disc. 
The disc was analyzed for 500 s. Main peaks detected (from right to left) are Molybdenum (Mo), 
Yttrium (Y), Rubidium (Rb), Bromine (Br), Zinc (Zn), Copper (Cu), Iron (Fe), Calcium (Ca), 
Potassium (K), Argon (Ar), Chlorine (Cl). Molybdenum detected inside the instrument; Argon 
detected from the air. keV – energy signature of elements. Pulse – intensity of secondary x-rays 
emitted by sample. The height of each peak shows the prevalence of each element in the sample.  
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Figure 4. TXRF Spectrum of murine midbrain sample. Mice treated with either 5 mg/kg METH 
or 0.9% Saline for 10 days. On Day 10, the mice were sacrificed and their brains removed. 
Brains were microdissected into PFC, STR, and MB. Microdissected brain segments were 
sonicated in RNase free water. 10 μL of Y was added to 100 μL of brain homogenate, and 10 μL 
of the mixture was pipetted onto an acrylic carrier disc. Samples were run three times (1000 s 
each), turned 1/3 each time, for a total run time of 3000 s. Main peaks detected (from right to 
left) are Molybdenum (Mo), Yttrium (Y), Rubidium (Rb), Bromine (Br), Zinc (Zn), Copper 
(Cu), Nickel (Ni), Iron (Fe), Titanium (Ti), Potassium (K), Argon (Ar), Chlorine (Cl). 
Molybdenum detected inside the instrument; Argon detected from the air. keV – energy 
signature of each element. Pulse – number of secondary x-rays emitted per primary x-ray emitted 
by the instrument. Height of each peak relates to the concentration of each element within the 
sample.  
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A.       B. 
             
C.  
             
Figure 5. Representative brain slices for Evans Blue Staining analysis of PFC. Bregma is 
determined as the point on the skull where coronal and sagittal sutures meet. Millimeter 
determinations anterior or posterior to bregma are given for each region. A. First PFC slice, 
approximately 2.80 mm anterior to bregma. B. Second PFC slice, approximately 1.94 mm 
anterior to bregma. C. Third PFC slice, approximately 1.10 mm anterior to bregma. Saline n=4; 
METH n=5. Yellow arrows indicate areas of blue staining within cortical blood vessels. 
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A.        B. 
             
Figure 6. Representative brain slices for Evans Blue Staining analysis of STR. Bregma is 
determined as the point on the skull where coronal and sagittal sutures meet. A. First STR slice, 
approximately 0.38 mm anterior to bregma. B. Second STR slice, approximately 1.34 mm 
posterior to bregma. Saline n=4; METH n=6. Yellow arrows indicate areas of blue staining 
within ventricles.  
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A.       B 
             
C.  
 
Figure 7. Representative brain slices for Evans Blue Staining analysis of MB. Bregma is 
determined as the point on the skull where coronal and sagittal sutures meet. A. First MB slice, 
approximately 2.80 mm posterior to bregma. B. Second MB slice, approximately 4.60 mm 
posterior to bregma. C. Third MB slice, approximately 5.68 mm posterior to bregma. Saline n=4; 
METH n=6. Yellow arrows indicate areas of blue staining. 
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A. 
 
B. 
 
Figure 8. IL-1β primer optimization and melting curve. Primer concentrations for optimization 
were established at 10 ng, 5 ng, 1 ng, 0.5 ng, 0.1 ng. qPCR cycling program setup: 50°C for 15 
minutes, 95°C for 15 minutes, 95°C for 15 seconds, 60°C for 30 seconds, 72°C for 30 seconds. 
A. PCR Product replication curves. Demonstrates that primers worked efficiently. B. Melting 
Curve. Demonstrates that primers were specific to the sequence of interest and only one product 
was created. Saline n=5; METH n=5.  
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A. 
 
B. 
 
Figure 9. MT3 primer optimization and melting curve. Primer concentrations for optimization 
were established at 10 ng, 5 ng, 1 ng, 0.5 ng, 0.1 ng. qPCR cycling program setup: 50°C for 15 
minutes, 95°C for 15 minutes, 95°C for 15 seconds, 55°C for 30 seconds, 72°C for 30 seconds.  
A. PCR Product replication curves. Demonstrates that primers worked efficiently. B. Melting 
Curve. Demonstrates that primers were specific to the sequence of interest and only one product 
was created. Saline n=5; METH n=5.  
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RESULTS 
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Significant Difference in Metal Concentrations in Midbrain 
PFC, STR, and MB microdissected from both Saline and METH-treated animals were analyzed 
by TXRF and data was recorded the following elements: Bromine (Br), Chlorine (Cl), Copper 
(Cu), Iron (Fe), Potassium (K), Nickel (Ni), Rubidium (Rb), Titanium (Ti), and Zinc (Zn) (Tables 
4-6). Three measurements were taken for each brain sample, to account for any uneven pipetting 
of brain homogenate. The three measurements for each sample were averaged to achieve a final 
value. The element concentrations for Saline and METH treatments were compared by a one-tailed 
two-sample t-test (α=0.05). Significant increases in the MB for the following elements were 
observed in METH-treated mice: Cl (Saline 2079.4 ± 502.04 µg/l; METH 4734.9 ± 1061.54 µg/l; 
p=0.03), K (Saline 44010 ± 5490.29 µg/l; METH 64724 ± 4085.13 µg/l; p=0.01), Zn (Saline 144.7 
± 16.44 µg/l; METH 210.3 ± 17.28 µg/l; p=0.01), and Rb (Saline 14.5 ± 2.21 µg/l; METH 25.2 ± 
3.44 µg/l; p=0.02) (Figures 10-12). When compared to Saline-treated mice, METH-treated mice 
had an increased elemental response to the drug. The increase in element concentrations was 
localized to the MB and did not appear in the PFC or STR. 
 
Elemental Analysis of Mouse Plasma 
Plasma was analyzed by TXRF and data was recorded for the following elements: Bromine (Br), 
Calcium (Ca), Chlorine (Cl), Copper (Cu), Iron (Fe), Potassium (K), Rubidium (Rb), Zinc (Zn) 
(Table 7). Elemental concentrations were analyzed by one-tailed two-sample t-test (α=0.05). 
Unlike what was seen in the brain, no significant changes in Cl (Saline 2138673 ± 470153 μg/l; 
METH 1424580 ± 416307 μg/l; p=0.14), K (Saline 207501 ± 56142.5 μg/l; METH 147498 ± 
48870.1 μg/l; p=0.22), Rb (Saline below lower limit of detection (LLD); METH (n=2) 46.59 ± 
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7.87 μg/l), or Zn (Saline 591.35 ± 47.12 μg/l; METH 532.53 ± 46.21 μg/l; p=0.19) were found 
between Saline-treated and METH-treated mice (Figure 13). Interestingly, a statistically 
significant decrease (p=0.04) in Fe concentration was found in METH-treated mice (2142.43 ± 
305.1 μg/l) as compared to Saline-treated controls (3060.89 ± 380.32 μg/l; figure 14). Rubidium 
concentrations were unable to be measured as they fell below the lower limit of detection (LLD; 
average LLD 45.31 ± 3.92 μg/l). Two Rb concentrations were above the LLD and quantified by 
the TXRF. Both samples were taken from METH-treated mice (38.73 and 54.46 μg/l).  
 
Superoxide Dismutase Activity in Brain Homogenate 
SOD inhibition rates were calculated based on measured absorbance values. Absorbance values 
give a comparative measure of the amount of SOD present in the sample. Based on the assay setup, 
percent inhibition of SOD and the initial amount of SOD present have an inverse relationship. The 
greater the amount of SOD inhibition, the less SOD is present in the initial sample. No significant 
difference was found in the percent SOD inhibition between Saline (89.34 ± 2.81%) and METH 
(92.01 ± 1.68%) treated groups in any region of the brain (Figure 15). Additional experiments 
examining the effects of protein amount and incubation time were run, to verify manufacturer 
protocols (Figure 16). The lack of difference in percent inhibition of SOD between Saline and 
METH-treated groups leads to the conclusion there was also no significant difference in the 
amount of SOD present between the samples.  
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Evidence of Blood-Brain Barrier Permeability via Evans Blue Assay 
Dissection of brain tissue and analysis of 8-bit color images revealed significant differences in 
Evans Blue permeability between Saline and METH-treated animals (Table 8). EB dye was most 
concentrated in blood vessels, as well as ventricles within the brain, as would be expected based 
on the circulation of EB. Within the tissue, no obvious large blue spots may be noted. However, 
densitometry analysis revealed significant increases in EB permeability occurred in the STR 
(p=0.03) and MB (p=0.01) of METH-treated animals when compared to Saline controls (Figure 
18). PFC data were nonsignificant (p=0.44), with much larger counts per pixel values than the 
other two brain regions. The lack of difference in PFC is likely due to the notable accumulation of 
EB in cortical blood vessels near the upper border of the PFC tissue samples, which would have 
artificially increased the counts per pixel values. 
 
Significant Changes in DNA Transcription via qPCR Analysis 
qPCR plates were analyzed for CT value, ΔCT value, and ΔΔCT value, as described previously. 
Two-tailed two-sample t-tests (α=0.05) were run to compare each ΔCT value for IL-1β and MT3 
from PFC, STR, and MB regions. A significant decrease in IL-1β was found in the midbrain of 
METH-treated mice as compared to Saline (p<0.05). No other significant changes in IL-1β were 
found in other brain regions, nor were significant changes of MT3 found in any brain region (Table 
9). Relative expression (fold change) of IL-1β and MT3 was determined by the ΔΔCT value and 
data is shown in Figures 19-21. 
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Table 4. Total Reflection X-Ray Fluorescence Spectroscopy values of murine prefrontal cortex. 
Brain samples taken from C57BL/6J mice treated with 5 mg/kg METH or 0.9% Saline by IP 
injection for 10 days. No significant concentration differences were determined between Saline 
and METH-treated mice. Saline n=6; METH n=6. One-tailed two-sample t-test; α=0.05. 
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Table 5. Total Reflection X-Ray Fluorescence Spectroscopy values of murine striatum. Brain 
samples taken from C57BL/6J mice treated with 5 mg/kg METH or 0.9% Saline by IP injection 
for 10 days. No significant concentration differences were determined between Saline and 
METH-treated mice. Saline n=6; METH n=6. One-tailed two-sample t-test; α=0.05. 
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Table 6. Total Reflection X-Ray Fluorescence Spectroscopy values of murine midbrain. Brain 
samples taken from C57BL/6J mice treated with 5 mg/kg METH or 0.9% Saline by IP injection 
for 10 days. Significant increases in Zn, Cl, K, and Rb were found in the midbrain of METH-
treated mice as compared to Saline controls. Saline n=6; METH n=6. One-tailed two-sample t-
test; α=0.05. *p<0.05 
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Table 7. Elemental concentrations in mouse plasma analyzed by TXRF. Plasma samples taken 
from C57BL6J mice treated with either 5 mg/kg METH or 0.9% Saline for 10 days were 
analyzed for elemental concentration. A significant decrease (p=0.04) in serum iron 
concentration was found in METH-treated mice as compared to Saline. Many of the sample 
levels of Rb fell below the lower limit of detection and therefore could not be measured. Saline 
n=6; METH n=6. One-tailed two-sample t-test; α=0.05. *p<0.05 **Rb METH treatment group: 
n=2.   
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Table 8. Counts per pixel measurements of Evans Blue permeability in Saline and METH-
treated mice. Nine brains (Saline n=4; METH n=5) were analyzed for EB leakage. One mm brain 
slices were grouped according to location in brain atlas. If any dissected brain region did not fit 
into a group or if the tissue was not able to be properly analyzed, it was excluded. Selected brain 
regions were dissected and photographed. 8-bit color images were analyzed for blue pigment 
concentration in ImageJ. Concentrations were averaged and treatment groups were analyzed for 
significance (α=0.05) by two-tailed two-sample t-test. *p<0.05 
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A. 
 
B. 
 
Table 9. Fold Change Values for IL-1β and MT3 mRNA Expression Determined via PCR. PCR 
was performed to amplify sequences for IL-1β (A) and MT3 (B) in purified mRNA from murine 
PFC, STR, and MB samples. ΔCT values were calculated to compare CT values from the 
housekeeping gene and gene of interest within each sample. ΔΔCT values were calculated to 
compare ΔCT values between METH and Saline treatment groups. Fold change was calculated 
using ΔΔCT values and is reported for IL-1β and MT3. Saline n=5; METH n=5. Two-tailed two-
sample t-tests were performed on ΔCT values; α=0.05. *p<0.05. 
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A.       B.  
 
C.       D. 
 
 
Figure 10. Elemental changes measured by TXRF in PFC of Saline and METH-treated mice. A. 
Chlorine concentrations in prefrontal cortex homogenate (p=0.22). B. Potassium concentrations 
in prefrontal cortex homogenate (p=0.46). C. Rubidium concentration in prefrontal cortex 
homogenate (p=0.32). D. Zinc concentration in prefrontal cortex homogenate (p=0.45). Saline 
n=6; METH n=6. One-tailed two-sample t-test; α=0.05.  
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A.       B. 
 
C.       D. 
 
Figure 11. Elemental changes measured by TXRF in STR of Saline and METH-treated mice. A. 
Chlorine concentration in striatum homogenate (p=0.40). B. Potassium concentration in striatum 
homogenate (p=0.43). C. Rubidium concentration in striatum homogenate (p=0.46). D. Zinc 
concentration in striatum homogenate (p=0.22). Saline n=6; METH n=6. One-tailed two-sample 
t-test; α=0.05.  
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A.       B.  
 
C.       D. 
 
Figure 12. Significant element increases in the midbrains of METH-treated mice. Zn, Cl, K, and 
Rb were increased after 10 days of treatment, as compared to Saline-treated mice. A) Chlorine 
concentration in midbrain homogenate (p=0.03). B) Potassium concentration in midbrain 
homogenate (p=0.01). C) Rubidium concentration in midbrain homogenate (p=0.02). D) Zinc 
concentration in midbrain homogenate (p=0.01). Saline n=6; METH n=6. One-tailed two-sample 
t-test; α=0.05. *p<0.05 
  
* * 
* * 
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A.       B. 
 
C.       D. 
 
Figure 13. Elemental concentrations in mouse plasma. After 10 days of treatment with either 
Saline or 5 mg/kg METH, mice were decapitated and trunk blood was collected. Plasma was 
isolated from blood and analyzed by TXRF. Saline n=9; METH n=9. A. Chlorine concentration 
from plasma sample (p=0.14). B. Potassium concentration from plasma sample (p=0.22). C. 
Rubidium concentration from plasma sample (n=2; 38.73 and 54.46 μg/l). D. Zinc concentration 
in plasma (p=0.19). One-tailed two-sample t-test (α=0.05).  
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Figure 14. Iron concentrations in mouse plasma. After 10 days of treatment with either Saline or 
5 mg/kg METH, mice were decapitated and trunk blood was collected. Plasma was isolated from 
blood and analyzed by TXRF. Saline n=9; METH n=9. Iron concentration in plasma (Saline 
3060.89 ± 380.32 μg/l; METH 2142.43 ± 503.01 μg/l; p=0.04). One-tailed two-sample t-test 
(α=0.05); *p<0.05. 
* 
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Figure 15. Percent inhibition of Copper-Zinc Superoxide Dismutase in mouse MB samples. 
Colorimetric assay (Abcam assay ab65354) was performed to determine percent inhibition of 
SOD enzyme in Saline and METH-treated samples. No significant difference was determined 
between Saline (89.34 ± 2.81%) and METH-treated (92.01 ± 1.68%) MB samples (p=0.21). 
Other brain regions also showed no significant differences between Saline and METH treatment 
groups. Saline n=6; METH n=7. One-tailed two-sample t-test; α=0.05. 
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A.       B. 
 
Figure 16. Protocol optimization of Copper-Zinc Superoxide Dismutase Assay. A) Percent 
Inhibition as a function of protein amount (g). Saline n=3; METH n=3. B) Percent inhibition as a 
function of incubation time (min). Saline n=6; METH n=7. One-tailed two-sample t-test; α=0.05. 
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A.        B. 
             
C.       D. 
             
E.       F. 
             
Figure 17. Whole brains after Evans Blue treatment. A & B. Brain from Saline-treated mouse (A. 
Dorsal surface; B. Ventral surface); frozen prior to analysis. Brain displayed a large amount of 
cortical EB staining. C & D. Brain from METH-treated mouse (C. Dorsal surface; D. Ventral 
surface); frozen prior to analysis. Brain displayed a moderate amount of cortical staining. E & F. 
Freshly dissected brain (E. Dorsal surface; F. Ventral surface); not previously frozen. Brain 
displayed a minimal amount of cortical staining. Brain frozen before analysis. Scale bar = 1 mm; 
7.5x magnification.  
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A.       B. 
 
C.       
 
Figure 18. Determination of Blood-Brain Barrier Permeability by Evans Blue Assay. 8-bit images 
of 1 mm PFC, STR, and MB slices were analyzed by the Histogram feature in ImageJ. Blue pixel 
counts were summed and divided to achieve standardized counts/pixel measurements. (A) PFC; 
p=0.442. (B) STR; p=0.032. (C) MB; p=0.012. Saline n=4; METH n=5. Two-tailed two-sample t-
test; α=0.05. *p<0.05 
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A.       B. 
 
C.       D. 
 
Figure 19. qPCR Data of IL-1β and MT3 from murine PFC. A. ΔCT values of IL-1B PFC. A 
significant increase in METH ΔCT value was determined as compared to Saline control 
(p=0.017). B. Fold Change from IL-1B PFC. Relative expression of IL-1β in METH-treated 
mice is downregulated two-fold of gene expression in Saline control mice.  C. ΔCT values from 
MT3 PFC. D. Fold Change from MT3 PFC. No significant differences exist between the 
treatment groups in regard to relative MT3 gene expression. Saline n=5; METH n=5. Two-tailed 
two-sample t-test; α=0.05. *p<0.05. 
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A.       B. 
 
C.       D. 
 
Figure 20. qPCR Data of IL-1β and MT3 from murine STR. A. ΔCT value for IL-1B STR. B. 
Fold Change for IL-1B STR. C. ΔCT value for MT3 STR. D. Fold Change for MT3 STR. Saline 
n=5; METH n=5. Two-tailed two-sample t-test; α=0.05.  
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A.      B. 
      
 
C.      D. 
      
Figure 21. qPCR Data of IL-1β and MT3 from murine MB. A. ΔCT value for IL-1B MB. A 
significant increase in ΔCT value was determined for METH-treated mice as compared to 
Saline-treated mice (p=0.049). B. Fold Change for IL-1B MB. IL-β expression in METH-treated 
mice is approximately half of the expression found in Saline-treated mice. C. ΔCT value for 
MT3 MB. D. Fold Change for MT3 MB. Saline n=5; METH n=5. Two-tailed two-sample t-test; 
α=0.05. *p<0.05. 
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DISCUSSION 
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Although some studies cite the use of Zn in attenuating the deleterious effects of METH in the 
brain (Aizenman et al., 2010; Ajjimaporn et al., 2005), our findings of both Zn and Rb 
accumulation in the MB following METH exposure appear to be novel. For the purposes of this 
thesis, our studies centered on Zn. Cl and K function as cell signaling ions with roles in neuronal 
signal propagation and cell responses. Therefore, it is likely increases in Cl and K concentrations 
are central to edema following METH treatment and the BBB disruption that typically precedes it 
(Kiatkin et al., 2007). Rb is a trace metal found in body tissues, with no known biological function. 
Due to their similarity in size and charge, K and Rb appear to have similar biological activities 
(Relman, 1956). Rb cannot be substituted for K in biological processes, but its presence often 
reflects the concentration of K in body tissues (Roberts et al., 2016). Recent studies present 
decreased concentrations of both K and Rb as characteristics of Alzheimer’s disease (Roberts et 
al., 2016). Though our studies did not include further investigation of the paired increase of both 
Rb and K, the future examination of Rb as a biomarker may prove useful. Naturally occurring 
radioactive isotopes of Rb may be examined by noninvasive scans. If scans show Rb is sequestered 
in a certain area, it is likely, because of their similar activities, K is also present in significant 
quantities. This may be useful in diagnosing edema related disorders, or other disorders that relate 
to large quantities of K present. Zn and K concentration surges may both be related to microglial 
activation and inflammatory stress (Knoch et al. 2008). 
 
Studies of excess zinc levels link high metal concentrations in many scenarios to the increased 
production of ROS, which leads to cell death (Ajjimaporn et al., 2005; Knoch et al., 2008; Sensi 
et al., 2009). Through our studies, we analyzed the amount of two free radical scavenging agents 
as possible mechanisms for the increase in zinc concentration. CuZnSOD is a free enzyme found 
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within cells that functions to neutralize free radicals in solution. It is well established that an 
increase in free radical species occurs following METH treatment (Ajjimaporn et al., 2005; Cubells 
et al., 1994; Friend et al., 2013). Therefore, we initially hypothesized that CuZnSOD enzymes are 
in greater demand in the brain, and carry with them excess Zn. The activity assay correlating 
inhibition of SOD to amount of SOD in solution determined there was no significant difference in 
SOD amount between Saline and METH-treated groups. Therefore, although Zn is an important 
cofactor in the activity of CuZnSOD, it does not appear to be the cause of the midbrain 
accumulation of Zn. MT3 is a brain specific cell membrane protein that functions to transport Zn 
in and out of cells, and possesses free radical scavenging properties when Zn ions are bound. We 
hypothesized that an increase in the Zn transporter concentration could be responsible for the 
excess deposition of zinc in the midbrain. However, qPCR analysis showed no significant 
difference in the amount of MT3 mRNA transcript between METH and Saline-treated mice. The 
lack of difference in mRNA produced gives no evidence for an increase in MT3 protein production. 
Based on these results, both SOD and MT3 appear to be unrelated to and perhaps unaffected by 
the increase in Zn in the midbrain after 10 days of METH treatment. Additional studies utilizing 
Western Blots would detect changes in the amount of formed protein products between treatment 
groups. Further experimentation examining changes in the concentration of other Zn-containing 
proteins or in the strength of the inflammatory responses would be useful in elucidating another 
mechanism of Zn entry. 
 
METH-induced inflammation via microglial activation causes neurons to release zinc from 
intracellular stores (Knoch et al., 2008). Also from the aforementioned study, microglia also cause 
an increase in K+ channel signaling. Both K+ and Zn2+ play roles in apoptotic cascades after 
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neuronal inflammation (Knoch et al., 2008). This leads us to believe microglial-derived 
inflammation plays a key role in METH toxicity. However, due to the decrease in cytokine IL-1β 
mRNA transcript in METH-treated animals, our qPCR analysis suggests a decrease in 
inflammation in the midbrain. Inflammation typically increases due to microglial activation with 
METH treatment (Fernandes et al., 2016); however, reports of attenuation due to tolerance may 
provide insight (Thomas & Kuhn, 2005). In the study by Thomas & Kuhn, pretreatment with 
METH doses significantly reduces the activation of microglia following challenge doses, even 
after a washout period of 7 days. Our data supports conclusions proposed by Thomas and Kuhn, 
as our chronic 10-day treatment with 5 mg/kg METH falls outside of their studied acclimation 
range of microglia. They do not propose a potential mechanism for the attenuation, only proposing 
that the acclimation of microglia in the striatum noted in their study has a neuroprotective function 
against further inflammatory damage following METH treatment. This decrease in inflammatory 
markers may also help explain what was seen in CuZnSOD and MT3 studies. CuZnSOD and MT3 
may act to neutralize free radicals as part of the immune response. However, if there is a lack of 
inflammation occurring, there is no substantive reason for those mechanisms to be upregulated 
inside of the cell. A decrease in TNF-α and IL-1β in cells under oxidative stress was noted after 
zinc supplementation in a study of effective treatments of atherosclerosis by Bao et al. 2010. 
Pretreatment with zinc often shows neuroprotective benefits against METH toxicity (Aizenman et 
al., 2010; Bao et al., 2010; Ajjimaporn et al., 2005). Therefore, we hypothesize the accumulation 
of zinc in vivo may have a neuroprotective effect against inflammation following METH treatment. 
Further studies are required to determine the relationship between microglial attenuation, a 
decrease in IL-1β cytokine mRNA, and zinc accumulation following METH treatment. 
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The transport of ions from the plasma into the brain under circumstances of METH intoxication 
may be facilitated by the BBB breakdown following METH-induced hyperthermia. As has been 
noted previously, we also observed statistically significant EB staining of METH-treated mice 
when compared to Saline controls. Using photographs and ImageJ analysis, we were able to verify 
the disruption of the BBB in two of the three areas directly affected by METH exposure, the STR 
and MB. Our study of the PFC showed nonsignificant results, likely due to the accumulation of 
EB in the cortical blood vessels. However, in future studies, perfusion of the animal with cold PBS 
following EB treatment and anesthesia would likely resolve this error and allow for a proper study 
of changes to PFC permeability. 
 
Due to the lower zinc concentration in the brain of Saline-treated mice when compared to METH-
treated mice, we hypothesized a higher average plasma zinc concentration would appear in Saline-
treated mice as compared to METH-treated mice. Our data supported our hypothesis through a 
modest decrease in zinc levels in plasma from METH-treated mice compared to Saline-treated 
mice. However, due to variability within the treatment groups, the values did not approach 
statistical significance (p=0.19). Iron concentrations in the plasma were significantly decreased 
(p=0.04).  The decrease in serum iron concentration may be related to the initial increase in splenic 
iron. If red blood cells accumulate in the spleen following METH treatment, as we presume to be 
causing the dark spots noted in our initial experiments, it would cause the drop in circulating iron 
concentration, as we see experimentally. Instrumental limitations prevented us from measuring 
levels of Rb in the plasma. The increase in the base LLD for Rb in plasma samples is likely due to 
refractory noise from the Br peak nearby. The peak for Br was artificially increased in plasma 
samples by IP injection of the anesthetic drug Avertin (2, 2, 2-tribromoethanol) before sacrifice. 
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Even though we were not able to analyze serum Rb concentrations to look for trends, the brain 
increase in Rb concentration is promising. Based on the literature and our data, the increase in Rb 
concentration in the brain after METH treatment may be a viable option for future use as a 
biomarker for neurodegeneration. 
 
METH intoxication has many deleterious effects, as supported by published literature (Carmena 
et al., 2015; Cubells et al., 1994; Emoto et al., 2015; Friend et al., 2013; Thomas & Kuhn, 2005). 
Elemental accumulation of Zn, K, Cl, and Rb in the midbrains of mice as a result of chronic METH 
treatment was observed compared to Saline-treated controls. Ion concentrations were measured in 
plasma, to understand if the values correlated to ion levels found in the brain. Although no 
significant correlations were found in Zn, K, Cl, and Rb, as were found, a significant decrease in 
Fe concentration was observed in METH-treated mice when compared to Saline.  In the brain 
tissue, no significant difference in SOD expression was found between METH and Saline-treated 
mice. PCR analysis of genes coding for MT3 showed no significant difference between METH 
and Saline-treated mice in any brain region. A significant decrease compared to Saline-treated 
mice was found in genes for IL-1β, a cytokine marker for inflammatory activity, via PCR analysis 
in the prefrontal cortex and midbrain of METH-treated mice. It is thought this significant decrease 
compared to controls may be an effect of microglial tolerance to the drug over the chronic 10-day 
treatment. A study of BBB permeability gave support to previous literature findings with 
disruptions in METH-treated groups that were not shown to the same degree in Saline-treated 
groups. An increase in permeability was seen between both STR and MB samples, but not in PCF, 
as the remaining EB in cortical blood vessels likely washed out any potential measurable 
difference. It is likely this disruption is linked to edema and influx of cell signaling ions and metals, 
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although the particular mechanism directly targeting the MB is currently unknown. A summary of 
these processes may be found in figure 22. 
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Figure 22. Summation of known and experimentally derived data. This chart attempts to display 
the complex interplay of the studies of this thesis. It is known in the literature that METH causes 
BBB leakage, edema through ion influx, and mitochondrial dysfunction. Our studies support the 
increase in ion concentration, including an influx of Rb (likely linked to the K influx) and also 
Zn accumulation. Significant BBB disruption was noted in STR and MB samples, potentially 
giving a potential point of entry for the accumulation of metals. Interestingly, our studies showed 
a decrease in IL-1β (a cytokine released by microglia) gene product, rather than an increase when 
compared to controls as would be expected following METH treatment. This surprising response 
is likely due to microglial tolerance to our chronic 10-day treatment of METH, though further 
studies are necessary to confirm this hypothesis. From the literature, it has been noted that excess 
zinc may be sequestered in mitochondria, leading to a disruption of the electron transport chain 
and ROS production. Though ROS production specifically was not a focus of our studies, the 
accumulation of zinc after METH treatment as compared to Saline in our studies may give a 
potential cause for the ROS production typically noted after METH treatment. 
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CONCLUSION 
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Our investigation into the neurodegeneration caused by chronic METH treatment has offered many 
valuable contributions to the field. C57BL/6J mice treated with chronic doses of METH show an 
accumulation of Zn, K, Rb, and Cl in the MB, as compared to Saline controls. Mice treated with 
METH for 10 days also show a decrease in inflammatory cytokines in both the PFC and MB, 
contrary to what is typically understood following METH treatment. Our studies suggested that 
the accumulation of zinc is not due to an increase in SOD enzymes present, nor an increase in the 
production of MT3 Zn-transporters in the brain. However, these results are supported by the 
decrease in inflammatory cytokine mRNA found via PCR. Both SOD and MT3 help neutralize 
free radicals, which may be released during the immune response. A lack of inflammation would 
not require the production of anti-inflammatory proteins, potentially giving us sound reasoning for 
the lack of significant differences between treatment groups in those studies. Increases in K may 
be linked to BBB leakage, and may be further studied via Rb biomarker studies, as the two 
elements share common accumulation patterns. BBB leakage was noted in the STR and MB, two 
regions directly activated by METH intoxication and studied here. No difference was noted in the 
PFC, likely because of the excess dye present in cortical blood vessels. Perfusion of the animal 
prior to brain dissection and analysis should remove this confound in future studies and allow for 
a clear look at the permeability of the PFC. The decrease in IL-1β mRNA concentration may be 
due to the tolerance of microglia for METH after a 10-day chronic treatment. Studies of varying 
length regarding METH treatment may be useful in determining the exact development of the zinc 
accumulation and elucidating its role in METH-induced neurodegeneration. The idea of microglial 
tolerance to METH-induced inflammation warrants further study to determine the exact 
mechanism and its possible relationship to Zn accumulation. Further studies of other inflammatory 
sources, like neuronal nitric oxide synthase (nNOS) production which has been found in increase 
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as a result of Zn excess, may also help elucidate a different facet of the role of Zn in RNS 
production and inflammation. 
Our studies contribute to the knowledge of metal accumulation following neurodegeneration, as is 
seen with other neurodegenerative disorders like Parkinson’s and Alzheimer’s disease. Though the 
mechanism of Zn accumulation is not yet known, our study of two potential mechanisms, both of 
which attenuate METH-induced damage when upregulated (Cadet et al., 1994; Imam et al., 2001; 
Ajjimaporn et al., 2005), point towards the necessity of different active mechanisms following 
METH intoxication. Although we have so far been unable to determine the mechanism directly 
targeting the MB or affecting the projection areas in PFC and STR, our studies provide support 
and valuable insight into the changes within the brain following METH exposure, and warrant 
further study. 
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